ASX - By Stock
|
ALA |
Re:
Ann: EGM Company Presentation
|
|
Bluebush
|
3 |
1.4K |
6 |
23/05/24 |
23/05/24 |
ASX - By Stock
|
3
|
1.4K
|
6
|
|
ASX - By Stock
|
ALA |
Re:
Arovella
|
|
Bluebush
|
6 |
3.1K |
0 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
6
|
3.1K
|
0
|
|
ASX - By Stock
|
ALA |
Arovella
|
|
Bluebush
|
6 |
3.1K |
10 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
6
|
3.1K
|
10
|
|
ASX - By Stock
|
NTI |
Re:
Ann: Positive Top-Line Rett Syndrome Clinical Trial Results
|
|
Bluebush
|
38 |
10K |
3 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
38
|
10K
|
3
|
|
ASX - By Stock
|
NTI |
Re:
Ann: Positive Top-Line Rett Syndrome Clinical Trial Results
|
|
Bluebush
|
38 |
10K |
2 |
11/05/24 |
11/05/24 |
ASX - By Stock
|
38
|
10K
|
2
|
|
ASX - By Stock
|
NTI |
Re:
Ann: Positive Top-Line Rett Syndrome Clinical Trial Results
|
|
Bluebush
|
38 |
10K |
6 |
09/05/24 |
09/05/24 |
ASX - By Stock
|
38
|
10K
|
6
|
|
ASX - By Stock
|
NTI |
Re:
Ann: Positive Top-Line Rett Syndrome Clinical Trial Results
|
|
Bluebush
|
38 |
10K |
4 |
07/05/24 |
07/05/24 |
ASX - By Stock
|
38
|
10K
|
4
|
|
ASX - By Stock
|
NTI |
Re:
Ann: Positive Top-Line Rett Syndrome Clinical Trial Results
|
|
Bluebush
|
38 |
10K |
2 |
07/05/24 |
07/05/24 |
ASX - By Stock
|
38
|
10K
|
2
|
|
ASX - By Stock
|
NTI |
Re:
Ann: Phase II/III ASD Trial Successfully Meets Primary Endpoint
|
|
Bluebush
|
49 |
13K |
8 |
03/05/24 |
03/05/24 |
ASX - By Stock
|
49
|
13K
|
8
|
|
ASX - By Stock
|
ALA |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Bluebush
|
3 |
2.2K |
3 |
30/04/24 |
30/04/24 |
ASX - By Stock
|
3
|
2.2K
|
3
|
|
ASX - By Stock
|
ALA |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Bluebush
|
3 |
2.2K |
5 |
30/04/24 |
30/04/24 |
ASX - By Stock
|
3
|
2.2K
|
5
|
|
ASX - By Stock
|
NTI |
Re:
Ann: Board Changes
|
|
Bluebush
|
2 |
631 |
3 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
2
|
631
|
3
|
|
ASX - By Stock
|
NTI |
Re:
Ann: Investor Webinar on Clinical Trial Results
|
|
Bluebush
|
3 |
1.1K |
1 |
17/04/24 |
17/04/24 |
ASX - By Stock
|
3
|
1.1K
|
1
|
|
ASX - By Stock
|
NTI |
Re:
Ann: Trading Halt
|
|
Bluebush
|
86 |
19K |
7 |
17/04/24 |
17/04/24 |
ASX - By Stock
|
86
|
19K
|
7
|
|
ASX - By Stock
|
NTI |
Re:
Ann: Trading Halt
|
|
Bluebush
|
86 |
19K |
0 |
17/04/24 |
17/04/24 |
ASX - By Stock
|
86
|
19K
|
0
|
|
ASX - By Stock
|
ALA |
Re:
Astellas gets first approval for Vyloy, in Japan
|
|
Bluebush
|
2 |
1.0K |
8 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
2
|
1.0K
|
8
|
|
ASX - By Stock
|
ALA |
Re:
Ann: Arovella to present at AACR annual meeting
|
|
Bluebush
|
3 |
1.1K |
2 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
3
|
1.1K
|
2
|
|
ASX - By Stock
|
ALA |
Re:
Ann: Trading Halt
|
|
Bluebush
|
32 |
13K |
1 |
24/03/24 |
24/03/24 |
ASX - By Stock
|
32
|
13K
|
1
|
|
ASX - By Stock
|
ALA |
Re:
Ann: Trading Halt
|
|
Bluebush
|
32 |
13K |
8 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
32
|
13K
|
8
|
|
ASX - By Stock
|
ALA |
Re:
Ann: ALA-101 and onCARlytics collaboration update
|
|
Bluebush
|
62 |
27K |
1 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
62
|
27K
|
1
|
|
ASX - By Stock
|
ALA |
Re:
Ann: ALA-101 and onCARlytics collaboration update
|
|
Bluebush
|
62 |
27K |
0 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
62
|
27K
|
0
|
|
ASX - By Stock
|
ALA |
Re:
Ann: ALA-101 and onCARlytics collaboration update
|
|
Bluebush
|
62 |
27K |
8 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
62
|
27K
|
8
|
|
ASX - By Stock
|
ALA |
FDA Approves First CAR T-Cell Therapy for Adults With Leukemia or Lymphoma
|
|
Bluebush
|
1 |
622 |
5 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
1
|
622
|
5
|
|
ASX - By Stock
|
ALA |
Re:
Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma
|
|
Bluebush
|
1 |
349 |
1 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
1
|
349
|
1
|
|
ASX - By Stock
|
ALA |
Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma
|
|
Bluebush
|
1 |
349 |
1 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
1
|
349
|
1
|
|
ASX - By Stock
|
ALA |
Cancer deaths in US spiked in 2021/22 (15-44 year-olds)
|
|
Bluebush
|
0 |
219 |
0 |
17/03/24 |
17/03/24 |
ASX - By Stock
|
0
|
219
|
0
|
|
ASX - By Stock
|
ALA |
Re:
Ann: Spark Plus Singapore Healthcare Day Presentation
|
|
Bluebush
|
9 |
2.4K |
9 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
9
|
2.4K
|
9
|
|
ASX - By Stock
|
ALA |
Re:
onCARlytics update
|
|
Bluebush
|
4 |
1.4K |
3 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
4
|
1.4K
|
3
|
|
ASX - By Stock
|
ALA |
onCARlytics update
|
|
Bluebush
|
4 |
1.4K |
6 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
4
|
1.4K
|
6
|
|
ASX - By Stock
|
ALA |
allogeneic hematopoietic cell transplantation
|
|
Bluebush
|
0 |
381 |
2 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
0
|
381
|
2
|
|
ASX - By Stock
|
ALA |
What are clinical trials?
|
|
Bluebush
|
0 |
397 |
3 |
23/02/24 |
23/02/24 |
ASX - By Stock
|
0
|
397
|
3
|
|
ASX - By Stock
|
ALA |
OnCarlytics trial
|
|
Bluebush
|
2 |
1.2K |
7 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
2
|
1.2K
|
7
|
|
ASX - By Stock
|
ALA |
CAR-T Relapse
|
|
Bluebush
|
3 |
2.0K |
7 |
03/02/24 |
03/02/24 |
ASX - By Stock
|
3
|
2.0K
|
7
|
|
ASX - By Stock
|
ALA |
Re:
Ann: Release of Shares from Escrow
|
|
Bluebush
|
3 |
1.2K |
0 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
3
|
1.2K
|
0
|
|
ASX - By Stock
|
ALA |
Re:
Ann: Trading Halt
|
|
Bluebush
|
10 |
5.1K |
2 |
29/01/24 |
29/01/24 |
ASX - By Stock
|
10
|
5.1K
|
2
|
|
ASX - By Stock
|
ALA |
Re:
Ann: Trading Halt
|
|
Bluebush
|
10 |
5.1K |
2 |
29/01/24 |
29/01/24 |
ASX - By Stock
|
10
|
5.1K
|
2
|
|
ASX - By Stock
|
ALA |
Re:
Ann: Trading Halt
|
|
Bluebush
|
10 |
5.1K |
2 |
29/01/24 |
29/01/24 |
ASX - By Stock
|
10
|
5.1K
|
2
|
|
ASX - By Stock
|
ALA |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Bluebush
|
7 |
2.8K |
1 |
28/01/24 |
28/01/24 |
ASX - By Stock
|
7
|
2.8K
|
1
|
|
ASX - By Stock
|
ALA |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Bluebush
|
7 |
2.8K |
0 |
26/01/24 |
26/01/24 |
ASX - By Stock
|
7
|
2.8K
|
0
|
|
ASX - By Stock
|
ALA |
Re:
Breakout Looming?
|
|
Bluebush
|
351 |
157K |
3 |
11/01/24 |
11/01/24 |
ASX - By Stock
|
351
|
157K
|
3
|
|
ASX - By Stock
|
ALA |
Re:
Breakout Looming?
|
|
Bluebush
|
351 |
157K |
8 |
10/01/24 |
10/01/24 |
ASX - By Stock
|
351
|
157K
|
8
|
|
ASX - By Stock
|
ALA |
Re:
Breakout Looming?
|
|
Bluebush
|
351 |
157K |
2 |
06/01/24 |
06/01/24 |
ASX - By Stock
|
351
|
157K
|
2
|
|
ASX - By Stock
|
ALA |
Re:
Breakout Looming?
|
|
Bluebush
|
351 |
157K |
9 |
30/12/23 |
30/12/23 |
ASX - By Stock
|
351
|
157K
|
9
|
|
ASX - By Stock
|
ALA |
Re:
Ann: CAR-iNKT Cell Platform Data Presented at ASH
|
|
Bluebush
|
6 |
4.0K |
8 |
12/12/23 |
12/12/23 |
ASX - By Stock
|
6
|
4.0K
|
8
|
|
ASX - By Stock
|
ALA |
Re:
Ann: Update on ALA-101 and onCARlytics research collaboration
|
|
Bluebush
|
12 |
5.1K |
8 |
05/12/23 |
05/12/23 |
ASX - By Stock
|
12
|
5.1K
|
8
|
|
ASX - By Stock
|
ALA |
Re:
Ann: Monsoon Twilight Investor Briefing Presentation
|
|
Bluebush
|
3 |
1.4K |
2 |
21/11/23 |
21/11/23 |
ASX - By Stock
|
3
|
1.4K
|
2
|
|
ASX - By Stock
|
ALA |
Re:
Ann: Monsoon Twilight Investor Briefing Presentation
|
|
Bluebush
|
3 |
1.4K |
2 |
21/11/23 |
21/11/23 |
ASX - By Stock
|
3
|
1.4K
|
2
|
|
ASX - By Stock
|
ALA |
Re:
Breakout Looming?
|
|
Bluebush
|
351 |
157K |
2 |
19/11/23 |
19/11/23 |
ASX - By Stock
|
351
|
157K
|
2
|
|
ASX - By Stock
|
ALA |
Re:
Ann: DKK1 program update following strategic pipeline review
|
|
Bluebush
|
3 |
1.2K |
5 |
13/11/23 |
13/11/23 |
ASX - By Stock
|
3
|
1.2K
|
5
|
|
ASX - By Stock
|
ALA |
Re:
Breakout Looming?
|
|
Bluebush
|
351 |
157K |
0 |
05/11/23 |
05/11/23 |
ASX - By Stock
|
351
|
157K
|
0
|
|